ArticleJCEM case reports2026
TTF-1-positive primary papillary epithelial tumor of the sella with long-term recurrence after multiple resections.
Article in JCEM case reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Primary papillary epithelial tumor of the sella is an extremely rare thyroid transcription factor-1 (TTF-1) positive tumor arising from the posterior pituitary and infundibular area and is often mistaken for a nonfunctioning pituitary adenoma. We report a young woman with a recurrent sellar-suprasellar mass over nearly a decade despite multiple transsphenoidal surgeries. The tumor showed progressive enlargement without hormone hypersecretion. Histopathology revealed a papillary epithelial neoplasm composed of bland cuboidal-to-columnar cells with apical snouting and inflammatory fibrovascular cores. Immunohistochemistry showed strong pancytokeratin, cytokeratin 7, and diffuse nuclear TTF-1 positivity, with negative pituitary hormone and transcription factor markers, confirming the diagnosis. The proliferation index was low. Complete excision was not feasible due to anatomical constraints, resulting in persistent residual disease. This case highlights the need to reconsider the diagnosis in long-standing recurrent sellar masses and emphasizes the importance of expert pathological assessment and prolonged follow-up in these rare tumors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.